MRD Application in Colorectal Cancer Patients

Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer

NCT03038217 ·Status: UNKNOWN ·Phase: PHASE3

The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer

NCT03416478 ·Status: UNKNOWN

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

NCT05969938 ·Status: UNKNOWN

MRD Test in Common Risk Stage II Colorectal Cancer

NCT05795010 ·Status: UNKNOWN

Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study

NCT05161585 ·Status: UNKNOWN ·Phase: NA

MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II)

NCT06879886 ·Status: NOT_YET_RECRUITING

MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis

NCT06434376 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1

Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence

NCT06143644 ·Status: ACTIVE_NOT_RECRUITING

Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer

NCT03573791 ·Status: RECRUITING

Molecular Study and Precision Medicine for Colorectal Cancer

NCT05883683 ·Status: NOT_YET_RECRUITING

Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer

NCT05444491 ·Status: ACTIVE_NOT_RECRUITING

Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer

NCT06831669 ·Status: RECRUITING

Chemoradiotherapy After Surgery Versus Preoperative Chemoradiotherapy for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors

NCT06566222 ·Status: NOT_YET_RECRUITING

Circulating Tumor DNA Methylation Guiding Postoperative Adjuvant Chemotherapy in Stage III Colorectal Cancer

NCT06167967 ·Status: RECRUITING ·Phase: NA

Diagnosis of Colorectal Cancer and Advanced Adenoma Using Cancer-specific Methylation Signatures

NCT03828396 ·Status: UNKNOWN

The Value of ctDNA on Chemotherapy Efficacy for mCRC

NCT04555369 ·Status: UNKNOWN ·Phase: NA

MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer

NCT06204484 ·Status: RECRUITING ·Phase: NA

CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients

NCT04917289 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial

NCT05755685 ·Status: UNKNOWN ·Phase: PHASE2

Response-adapted Total Neoadjuvant Therapy Guided by Induction Chemotherapy in Early- and Intermediate-risk Low Rectal Cancer for Implementation of a Watch-and-wait Strategy

NCT07260526 ·Status: RECRUITING

Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer

NCT01012804 ·Status: WITHDRAWN

Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention

NCT05635630 ·Status: RECRUITING ·Phase: NA

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

NCT05155124 ·Status: UNKNOWN ·Phase: PHASE1

Tumor Response Prediction in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer Using Metabonomics Analysis

NCT03149978 ·Status: UNKNOWN

ctDNA for Prediction of Relapse in Gastric Cancer

NCT02887612 ·Status: UNKNOWN